SBI-425 | CAS# 1451272-71-1 | TNAP Inhibitor

MedKoo Cat#: 563833 | Name: SBI-425

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SBI-425 is a potent, selective and orally bioavailable compound that robustly inhibits tissue-nonspecific alkaline phosphatase (TNAP) in vivo.

Chemical Structure

SBI-425

CAS#1451272-71-1

Theoretical Analysis

MedKoo Cat#: 563833

Name: SBI-425

CAS#: 1451272-71-1

Chemical Formula: C13H12ClN3O4S

Exact Mass: 341.0237

Molecular Weight: 341.77

Elemental Analysis: C, 45.69; H, 3.54; Cl, 10.37; N, 12.30; O, 18.73; S, 9.38

Price and Availability

Size	Price	Availability
5mg	USD 295.00	2 Weeks
10mg	USD 425.00	2 Weeks
25mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SBI-425; SBI-425; SBI-425

IUPAC/Chemical Name

5-((5-Chloro-2-methoxyphenyl)sulfonamido)nicotinamide

InChi Key

SBAITEDLNTYIOE-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H12ClN3O4S/c1-21-11-3-2-9(14)5-12(11)22(19,20)17-10-4-8(13(15)18)6-16-7-10/h2-7,17H,1H3,(H2,15,18)

SMILES Code

O=C(N)C1=CN=CC(NS(=O)(C2=CC(Cl)=CC=C2OC)=O)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 341.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Spinelli P, Fields AM, Falcone S, Mesaros C, Susiarjo M. Susceptibility to Low Vitamin B6 Diet-induced Gestational Diabetes Is Modulated by Strain Differences in Mice. Endocrinology. 2023 Aug 28;164(10):bqad130. doi: 10.1210/endocr/bqad130. PMID: 37624591; PMCID: PMC10686696. 2: Opdebeeck B, Neven E, Maudsley S, Leysen H, Walter D, Geryl H, D'Haese PC, Verhulst A. A Proteomic Screen to Unravel the Molecular Pathways Associated with Warfarin-Induced or TNAP-Inhibited Arterial Calcification in Rats. Int J Mol Sci. 2023 Feb 11;24(4):3657. doi: 10.3390/ijms24043657. PMID: 36835062; PMCID: PMC9963640. 3: Sebinelli HG, Andrilli LHS, Favarin BZ, Cruz MAE, Bolean M, Fiore M, Chieffo C, Magne D, Magrini A, Ramos AP, Millán JL, Mebarek S, Buchet R, Bottini M, Ciancaglini P. Shedding Light on the Role of Na,K-ATPase as a Phosphatase during Matrix-Vesicle-Mediated Mineralization. Int J Mol Sci. 2022 Dec 1;23(23):15072. doi: 10.3390/ijms232315072. PMID: 36499456; PMCID: PMC9739803. 4: Bessueille L, Kawtharany L, Quillard T, Goettsch C, Briolay A, Taraconat N, Balayssac S, Gilard V, Mebarek S, Peyruchaud O, Duboeuf F, Bouillot C, Pinkerton A, Mechtouff L, Buchet R, Hamade E, Zibara K, Fonta C, Canet-Soulas E, Millan JL, Magne D. Inhibition of alkaline phosphatase impairs dyslipidemia and protects mice from atherosclerosis. Transl Res. 2023 Jan;251:2-13. doi: 10.1016/j.trsl.2022.06.010. Epub 2022 Jun 17. PMID: 35724933. 5: Opdebeeck B, Neven E, Millán JL, Pinkerton AB, D'Haese PC, Verhulst A. Chronic Kidney Disease-Induced Arterial Media Calcification in Rats Prevented by Tissue Non-Specific Alkaline Phosphatase Substrate Supplementation Rather Than Inhibition of the Enzyme. Pharmaceutics. 2021 Jul 26;13(8):1138. doi: 10.3390/pharmaceutics13081138. PMID: 34452102; PMCID: PMC8399849. 6: Opdebeeck B, Neven E, Millán JL, Pinkerton AB, D'Haese PC, Verhulst A. Pharmacological TNAP inhibition efficiently inhibits arterial media calcification in a warfarin rat model but deserves careful consideration of potential physiological bone formation/mineralization impairment. Bone. 2020 Aug;137:115392. doi: 10.1016/j.bone.2020.115392. Epub 2020 Apr 30. PMID: 32360899; PMCID: PMC8406684. 7: Opdebeeck B, D'Haese PC, Verhulst A. Inhibition of tissue non-specific alkaline phosphatase; a novel therapy against arterial media calcification? J Pathol. 2020 Mar;250(3):248-250. doi: 10.1002/path.5377. Epub 2020 Jan 12. PMID: 31859361. 8: Brichacek AL, Benkovic SA, Chakraborty S, Nwafor DC, Wang W, Jun S, Dakhlallah D, Geldenhuys WJ, Pinkerton AB, Millán JL, Brown CM. Systemic inhibition of tissue-nonspecific alkaline phosphatase alters the brain-immune axis in experimental sepsis. Sci Rep. 2019 Dec 11;9(1):18788. doi: 10.1038/s41598-019-55154-2. PMID: 31827139; PMCID: PMC6906465. 9: Nwafor DC, Chakraborty S, Brichacek AL, Jun S, Gambill CA, Wang W, Engler- Chiurazzi EB, Dakhlallah D, Pinkerton AB, Millán JL, Benkovic SA, Brown CM. Loss of tissue-nonspecific alkaline phosphatase (TNAP) enzyme activity in cerebral microvessels is coupled to persistent neuroinflammation and behavioral deficits in late sepsis. Brain Behav Immun. 2020 Feb;84:115-131. doi: 10.1016/j.bbi.2019.11.016. Epub 2019 Nov 25. PMID: 31778743; PMCID: PMC7010562. 10: Tani T, Fujiwara M, Orimo H, Shimizu A, Narisawa S, Pinkerton AB, Millán JL, Tsuruoka S. Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model. J Pathol. 2020 Jan;250(1):30-41. doi: 10.1002/path.5346. Epub 2019 Nov 23. PMID: 31509234; PMCID: PMC7238767. 11: Li Q, Huang J, Pinkerton AB, Millan JL, van Zelst BD, Levine MA, Sundberg JP, Uitto J. Inhibition of Tissue-Nonspecific Alkaline Phosphatase Attenuates Ectopic Mineralization in the Abcc6-/- Mouse Model of PXE but Not in the Enpp1 Mutant Mouse Models of GACI. J Invest Dermatol. 2019 Feb;139(2):360-368. doi: 10.1016/j.jid.2018.07.030. Epub 2018 Aug 18. PMID: 30130617; PMCID: PMC6342656. 12: Pinkerton AB, Sergienko E, Bravo Y, Dahl R, Ma CT, Sun Q, Jackson MR, Cosford NDP, Millán JL. Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor. Bioorg Med Chem Lett. 2018 Jan 1;28(1):31-34. doi: 10.1016/j.bmcl.2017.11.024. Epub 2017 Nov 11. PMID: 29174347; PMCID: PMC5731646. 13: Romanelli F, Corbo A, Salehi M, Yadav MC, Salman S, Petrosian D, Rashidbaigi OJ, Chait J, Kuruvilla J, Plummer M, Radichev I, Margulies KB, Gerdes AM, Pinkerton AB, Millán JL, Savinov AY, Savinova OV. Overexpression of tissue- nonspecific alkaline phosphatase (TNAP) in endothelial cells accelerates coronary artery disease in a mouse model of familial hypercholesterolemia. PLoS One. 2017 Oct 12;12(10):e0186426. doi: 10.1371/journal.pone.0186426. PMID: 29023576; PMCID: PMC5638543. 14: Sheen CR, Kuss P, Narisawa S, Yadav MC, Nigro J, Wang W, Chhea TN, Sergienko EA, Kapoor K, Jackson MR, Hoylaerts MF, Pinkerton AB, O'Neill WC, Millán JL. Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification. J Bone Miner Res. 2015 May;30(5):824-36. doi: 10.1002/jbmr.2420. PMID: 25428889; PMCID: PMC4406354.